Alzheimer's DiseasePhase 3NCT06653153
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
A Phase 3 study testing Remternetug in people with Alzheimer's Disease, run by Eli Lilly and Company at 262 sites in 10 countries.
Trial summary
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Read more about this study
- Who is it for?
- Ages 55 to 80 years
- Conditions the study is for
- Alzheimer's Disease
- What is being tested?
- Remternetug
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1,400 participants
- Where
- 262 sitesin 10 countries
- Study dates
- 24 Oct 2024to Oct 2030
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Have a phosphorylated tau (P-tau) result consistent with the presence of amyloid pathology.
- Have a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.
- Have adequate literacy, vision, and hearing for neuropsychological testing at screening.
- Have a Mini Mental Status Exam (MMSE) score consistent with no to minimal cognitive impairment.
- Have a Functional Activities Questionnaire (FAQ) score consistent with no to minimal functional impairment.
- If currently receiving medications as symptomatic treatment for AD, dose has been stable for at least 30 days before screening.
Who cannot join
- Have dementia or significant other neurological disease that can affect cognition.
- Have current serious or unstable illnesses that in the investigator's opinion, could interfere with the analyses of the study.
- Have a history of cancer that, in the investigator's opinion, has a high risk of recurrence.
- Have a history of clinically significant multiple or severe drug allergies, or hypersensitivity reactions.
- Have a clinically important laboratory test result or other abnormality as determined by investigator, prior to randomization, that could be detrimental to the participant or could compromise the study.
- Have any contraindications for magnetic resonance imaging (MRI).
Show all 10Show fewer
- Have a centrally read MRI that does not meets study entry criteria.
- Prior or Current Therapies
- Have ever had prior treatment with a passive anti-amyloid immunotherapy.
- Have received active immunization against Aβ in any other study.
Trial locations and contacts
262 sites in 10 countries.
262 sites in 10 countries
United States123 sites
IMA Clinical Research
Albuquerque, New Mexico, 87109
Care Access - Arlington 2
Arlington, Virginia, 22206
Care Access - Arlington Heights
Arlington Heights, Illinois, 60005
JEM Research Institute
Atlantis, Florida, 33462
Care Access - Aurora
Aurora, Colorado, 80012
Senior Adults Specialty Research
Austin, Texas, 78757
VIN - Aventura
Aventura, Florida, 33180
Care Access - Baltimore
Baltimore, Maryland, 21213
Acadia Hospital
Bangor, Maine, 04401
Mountain Neurological Research Center
Basalt, Colorado, 81621
Gadolin Research
Beaumont, Texas, 77702
Northwest Clinical Research Center
Bellevue, Washington, 98007
Parkway Medical Center
Birmingham, Alabama, 35215
Northwest Clinical Trials
Boise, Idaho, 83704
Citizens Memorial Hospital District
Bolivar, Missouri, 65613
Adams Clinical Boston
Boston, Massachusetts, 02116
Boston Clinical Trials
Boston, Massachusetts, 02131
Alpine Clinical Research Center
Boulder, Colorado, 80301
Bradenton Research Center, Inc.
Bradenton, Florida, 34205
MD First Research - Chandler
Chandler, Arizona, 85286
Care Access - Charlotte
Charlotte, North Carolina, 28210
Clinical Research Professionals
Chesterfield, Missouri, 63005
Re:Cognition Health - Chicago
Chicago, Illinois, 60611
Great Lakes Clinical Trials - Andersonville
Chicago, Illinois, 60640
K2 Medical Research WINTER GARDEN
Clermont, Florida, 34711
Columbus Memory Center, LLC
Columbus, Georgia, 31909
Neurology Clinic, P.C.
Cordova, Tennessee, 38018
Kerwin Medical Center - Oak Cliff
Dallas, Texas, 75216
Kerwin Medical Center
Dallas, Texas, 75231
TecTum Research
Davie, Florida, 33024
Revival Research Institute, LLC
Dearborn, Michigan, 48126
Care Access - Decatur
Decatur, Georgia, 30030
Brain Matters Research
Delray Beach, Florida, 33445
Rhode Island Mood & Memory Research Institute
East Providence, Rhode Island, 02914
Alexian Brothers Medical Center
Elk Grove Village, Illinois, 60007
CenExel Rocky Mountain Clinical Research
Englewood, Colorado, 80113
Re:Cognition Health
Fairfax, Virginia, 22031
QUEST Research Institute
Farmington Hills, Michigan, 48334
Neuropsychiatric Research Center of Southwest Florida
Fort Myers, Florida, 33912
Neuro-Pain Medical Center
Fresno, California, 93710
Center for Advanced Research & Education
Gainesville, Georgia, 30501
Care Access - Georgetown
Georgetown, Texas, 78633
Medication Management
Greensboro, North Carolina, 27405
Tribe Clinical Research, LLC- Greenville
Greenville, South Carolina, 29607
Private Practice - Dr. Ronald Louis Schwartz
Hattiesburg, Mississippi, 39401
Indago Research & Health Center, Inc
Hialeah, Florida, 33012
Care Access - Hoboken
Hoboken, New Jersey, 07030
Care Access - Houston
Houston, Texas, 77054
The University of Texas Health Science Center at Houston
Houston, Texas, 77054
Next Level Urgent Care
Houston, Texas, 77057
Care Access - Huntington Beach
Huntington Beach, California, 92648
Care Access - South Indianapolis
Indianapolis, Indiana, 46227
Josephson Wallack Munshower Neurology, PC
Indianapolis, Indiana, 46256
Inglewood Clinical
Inglewood, California, 90301
Irvine Clinical Research
Irvine, California, 92614
Genesis Neuroscience Clinic
Knoxville, Tennessee, 37909
K2 MEDICAL Research THE VILLAGES
Lady Lake, Florida, 32159
Care Access - Lake Charles (Bayou Pines)
Lake Charles, Louisiana, 70601
Vector Clinical Trials
Las Vegas, Nevada, 89128
Care Access - Lima
Lima, Ohio, 45805
Healthy Brain Clinic
Long Beach, California, 90804
ClinCloud
Maitland, Florida, 32751
K2 Medical Research ORLANDO
Maitland, Florida, 32751
Tandem Clinical Research
Marrero, Louisiana, 70072
ClinCloud
Melbourne, Florida, 32940
Merritt Island Medical Research, LLC
Merritt Island, Florida, 32952
Care Access - 801 South Power Road, Mesa
Mesa, Arizona, 85206
VIN-Andrew Lerman
Miami, Florida, 33133
New Age Medical Research Corporation
Miami, Florida, 33186
North Star Medical Research
Middleburg Heights, Ohio, 44130
Monroe Biomedical Research
Monroe, North Carolina, 28112
Adult Medicine of Lake County, Inc.
Mt. Dora, Florida, 32757
Aqualane Clinical Research
Naples, Florida, 34105
Invicro
New Haven, Connecticut, 06510
Suncoast Clinical Research, Inc.
New Port Richey, Florida, 34652
Boston Center for Memory
Newton, Massachusetts, 02459
Eastern Virginia Medical School (EVMS) Medical Group
Norfolk, Virginia, 23510
Renstar Medical Research
Ocala, Florida, 34470
University Of Nebraska Medical Center
Omaha, Nebraska, 68198
Charter Research - Winter Park
Orlando, Florida, 32803
AdventHealth Orlando
Orlando, Florida, 32804
Emerald Coast Neurology - Airport Boulevard
Pensacola, Florida, 32504
Clinical Research of Philadelphia
Philadelphia, Pennsylvania, 19114
Banner Alzheimer's Institute
Phoenix, Arizona, 85006
Keystone Clinical Studies
Plymouth Meeting, Pennsylvania, 19462
Progressive Medical Research
Port Orange, Florida, 32127
Summit Headlands
Portland, Oregon, 97210
Butler Hospital
Providence, Rhode Island, 02906
Care Access - Quincy
Quincy, Massachusetts, 02169
Rainier Clinical Research Center
Renton, Washington, 98057
The Cognitive and Research Center of New Jersey - Ridgewood
Ridgewood, New Jersey, 07450
El Faro Health and Therapeutics
Rio Grande City, Texas, 78582
Riverside Clinical
Riverside, California, 92506
Central Texas Neurology Consultants, PA
Round Rock, Texas, 78681
Clinical Trials Research
Sacramento, California, 95821
HealthPartners Neuroscience Center
Saint Paul, Minnesota, 55130
IMA Clinical Research San Antonio
San Antonio, Texas, 78229
Artemis Institute for Clinical Research
San Diego, California, 92103
Sharp Neurocognitive Research Center
San Diego, California, 92123
Ray Dolby Brain Health Center
San Francisco, California, 94114
The Neuron Clinic - San Marcos
San Marcos, California, 92069
Syrentis Clinical Research
Santa Ana, California, 92705
Providence Medical Foundation
Santa Rosa, California, 95403
Consano Clinical Research, LLC
Shavano Park, Texas, 78231
California Neuroscience Research, LLC
Sherman Oaks, California, 91403
The Cognitive and Research Center of New Jersey
Springfield, New Jersey, 07081
Ki Health Partners, LLc, dba New England Institute for Clinical Research
Stamford, Connecticut, 06905
Alzheimer's Research and Treatment Center
Stuart, Florida, 34997
Palmetto Clinical Research
Summerville, South Carolina, 29485
Axiom Brain Health LLC
Tampa, Florida, 33609
Stedman Clinical Trials
Tampa, Florida, 33613
Care Access - Tampa
Tampa, Florida, 33625
Charter Research - Lady Lake
The Villages, Florida, 32162
Advanced Memory Research Institute of New Jersey
Toms River, New Jersey, 08755
Cotton O'Neil Clinical Research Center
Topeka, Kansas, 66606
Banner Alzheimer's Institute Tucson
Tucson, Arizona, 85718
MedVadis Research Corporation
Waltham, Massachusetts, 02451
Cedar Valley Medical Specialists
Waterloo, Iowa, 50701
Adams Clinical Watertown
Watertown, Massachusetts, 02472
Alzheimer's Research and Treatment Center
Wellington, Florida, 33414
Palm Beach Neurology
West Palm Beach, Florida, 33407
Conquest Research
Winter Park, Florida, 32789
North Georgia Clinical Research
Woodstock, Georgia, 30189
China29 sites
Beijing Tiantan Hospital Affiliated to Capital Medical University
Beijing, 100071
Beijing Anding Hospital - Affiliated Capital University of Medical Science
Beijing, 100088
The First Hospital of Jilin University
Changchun, 100012
Xiangya Hospital Central South University
Changsha, 410008
Sichuan Provincial People's Hospital
Chengdu, 610072
Guangdong Provincial People's Hospital
Guangzhou, 510080
Guangzhou First People's Hospital
Guangzhou, 510180
Guangzhou Medical University 2nd Hospital
Guangzhou, 510260
Zhujiang Hospital
Guangzhou, 510280
Anhui Provincial Hospital
Hefei, 230036
Jinan Central Hospital
Jinan, 250013
The First Affiliated Hospital of Henan University of Science &Technology
Luoyang, 471003
The Second Affiliated Hospital of Nanchang University
Nanchang, 330000
The First Affiliated Hospital of Nanchang University
Nanchang, 330006
Nanjing Brain Hospital
Nanjing, 210029
Sir Run Run Hospital of Nanjing Medical University
Nanjing, 211166
Shanghai Sixth People's Hospital
Shanghai, 200030
Huashan Hospital, Fudan University
Shanghai, 200040
Renji Hospital Shanghai Jiao Tong University School of Medicine
Shanghai, 200135
Pudong New Area People's Hospital Shanghai
Shanghai, 201200
The First Hospital of Hebei Medical University
Shijiazhuang, 050031
The Second Affiliated Hospital of Soochow University
Suzhou, 215004
Tianjin Medical University General Hospital
Tianjin, 300052
Shaanxi provincial people's hospital
Xi'an, 710068
The First Affiliated Hospital of Xi'an Medical University
Xi'an, 710077
Xianyang Hospital of Yan'an University
Xianyang, 712000
The Affiliated Hospital of Xuzhou Medical College
Xuzhou, 221006
Xuzhou Central Hospital
Xuzhou, 221018
Zigong First People's Hospital
Zigong, 643000
Japan27 sites
The University of Tokyo Hospital
Bunkyō City, 113-8655
Medical Corporation Chiseikai Tokyo Center Clinic
Chūōku, 103-0027
Tokyo-Eki Center-building Clinic
Chūōku, 103-0027
Fukuwa Clinic
Chūōku, 104-0031
Tokyo Asbo Clinic
Chūōku, 104-0031
Kawashima Neurology Clinic
Fujisawa, 251-0038
UNB Sumiyoshi Jinjamae Clinic
Fukuoka, 812-0018
Boocs Clinic Fukuoka
Fukuoka, 812-0025
P-One Clinic
Hachiōji, 192-0071
Hyogo Prefectural Harima-Himeji General Medical Center
Himeji, 670-8560
Saiseikai Imabari Hospital
Imabari, 799-1592
Kobe University Hospital
Kobe, 650-0017
Showa General Hospital
Kodaira, 187-8510
Tatsuoka Neurology Clinic
Kyoto, 600-8811
Sakurazaka Clinic SophyAnce
Minatoku, 106-0032
National Center for Geriatrics and Gerontology
Ōbu, 474-8511
Iwata Neurosurgery Clinic
Osaka, 536-0007
Kanto Central Hospital
Setagaya-ku, 158-8531
Samoncho Clinic
Shinjuku, 160-0017
Clinical Research Hospital Tokyo
Shinjuku-ku, 160-0004
Heishinkai Medical Group ToCROM Clinic
Shinjuku-ku, 160-0008
Higashi Shinjuku Clinic
Shinjuku-ku, 169-0072
Medical Corporation Heishinkai OCROM Clinic
Suita-shi, 565-0853
Tokyo Metropolitan Geriatric Hospital
tabashi City, 173-0015
Tachikawa Hospital
Tachikawa, 190-8531
Takatsuki Hospital
Takatsuki-shi, 569-1192
Wako Hospital
Wako, 351-0111
Canada17 sites
Ecogene-21 - Cmas
Chicoutimi, G7H 0S7
MoCA Research and Innovation Inc.
Greenfield Park, J4V 2J2
OCT Research ULC
Kelowna, V1Y 1Z9
Alpha Recherche Clinique - Lévis
Lévis, G6V 0C9
Clinique Mémoire de Montréal
Montreal, H3G 1H9
Genge Partners
Montreal, H4A 3T2
Ottawa Memory Clinic
Ottawa, K1Z 1G3
Kawartha Centre - Redefining Healthy Aging
Peterborough, K9H 2P4
Alpha Recherche Clinique
Québec, G2J 0C4
ALPHA Recherche Clinique
Québec, G3K 2P8
Bluewater Clinical Research Group Inc.
Sarnia, N7T 4X3
Q&T Research Sherbrooke Inc.
Sherbrooke, J1J 2G2
Toronto Memory Program
Toronto, M3B 2S7
Sunnybrook Research Institute
Toronto, M4N 3M5
Baycrest Health Sciences
Toronto, M6A 2E1
Diex Recherche Inc. Division Victoriaville
Victoriaville, G6P 3Z8
The Medical Arts Health Research Group - West Vancouver
West Vancouver, V7T 1C5
South Korea17 sites
Pusan National University Hospital
Busan, 49241
Chungbuk National University Hospital
Cheongju-si, 28644
Gangnam Severance Hospital, Yonsei University Health System
Gangnam-gu, 06273
Ewha Womans University Seoul Hospital
Gangseo-gu, 07804
Chonnam National University Hospital
Gwangju, 61469
Inha University Hospital
Incheon, 22332
Jeju National University Hospital
Jeju City, 63241
Gachon University Gil Medical Center
Namdong-gu, 21565
Seoul National University Bundang Hospital
Seongnam, 13620
Seoul National University Hospital
Seoul, 03080
Hanyang University Seoul Hospital
Seoul, 04763
Konkuk University Medical Center
Seoul, 05030
Asan Medical Center
Seoul, 05505
Samsung Medical Center
Seoul, 06351
The Catholic Univ. of Korea Seoul St. Mary's Hospital
Seoul, 06591
Ajou University Hospital
Suwon, 16499
Wonju Severance Christian Hospital
Wŏnju, 26426
Australia16 sites
USC Clinical Trials Sunshine Coast
Birtinya, 4575
Emeritus Research
Botany, 2019
Box Hill Hospital
Box Hill, 3128
Emeritus Research
Camberwell, 3124
GenesisCare - Maitland
East Maitland, 2323
The University of Queensland
Herston, 4029
Ipswich Hospital
Ipswich, 4305
Austin Health
Ivanhoe, 3079
Southern Neurology
Kogarah, 2217
KARA Institute for Neurological Diseases
Macquarie Park, 2113
HammondCare
Malvern, 3144
Fusion Clinical Research
Norwood, 5067
The Royal Melbourne Hospital
Parkville, 3050
USC Clinical Trials Brisbane (South Bank)
South Brisbane, 4101
St Vincent's Hospital
Sydney, 2010
The Queen Elizabeth Hospital
Woodville, 5011
United Kingdom12 sites
ReMind UK
Bath, BA1 3NG
Re:Cognition Health - Birmingham
Birmingham, B16 8LT
Layton Medical Centre
Blackpool, FY3 7EN
Scottish Brain Sciences
Edinburgh, EH12 5PJ
St Pancras Clinical Research
London, EC2Y 8EA
NIHR Manchester Clinical Research Facility
Manchester, M13 9WL
NeuroClin
Motherwell, ML1 4UF
Roborough Surgery
Plymouth, PL6 6PH
Homecroft Surgery
Redruth, TR16 4ET
Abbeywell Surgery
Romsey, SO51 7QN
Moorgreen Hospital
Southampton, SO30 3JB
Marine Lake Medical Practice
West Kirby, CH48 5AA
Taiwan10 sites
Changhua Christian Hospital
Changhua County, 50006
National Taiwan University Hospital Yun-Lin Branch Dou-Liou Region
Douliu, 640
Chang Gung Memorial Hospital at Kaohsiung
Kaohsiung Niao Sung Dist, 83301
Taipei Medical University Shuang Ho Hospital
New Taipei City, 235
New Taipei Municipal TuCheng Hospital
New Taipei City, 236
China Medical University Hospital
Taichung, 404332
Taichung Veterans General Hospital
Taichung, 407
National Taiwan University Hospital
Taipei, 10002
Taipei Veterans General Hospital
Taipei, 11217
Chang Gung Medical Foundation-Linkou Branch
Taoyuan, 333
Spain7 sites
Barcelonabeta Brain Research Center
Barcelona, 08005
Fundació ACE
Barcelona, 08028
Hospital Clínic de Barcelona
Barcelona, 08036
Hospital de la Santa Creu i Sant Pau
Barcelona, 08041
Hospital Universitario Quironsalud Madrid
Pozuelo de Alarcón, 28223
Policlinica Gipuzkoa
San Sebastián, 20014
Hospital Victoria Eugenia
Seville, 41009
Puerto Rico4 sites
SCB Research Center
Bayamón, 00961
Caribbean Medical Research Center
San Juan, 00918
INSPIRA Clinical Research
San Juan, 00918
Instituto De Neurologia Dra. Ivonne Fraga
San Juan, 00918
About this study
Official title: A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo.
Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period.
- Conditions
- Alzheimer's Disease
- Being tested
- Remternetug, Placebo
- Medical subject headings
- Alzheimer Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RemternetugDrug
Also called LY3372993
Administered SC
PlaceboDrug
Administered SC
| Study group | Role | What they receive |
|---|---|---|
| Remternetug | Experimental | Remternetug administered subcutaneously (SC). Receives: Drug: Remternetug |
| Placebo | Placebo comparator | Placebo administered SC. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to Clinically Meaningful Progression as Measured by Clinical Dementia Rate Scale (CDR)
Time to clinically meaningful progression as measured by CDR. CDR is a clinician-rated scale that provides an overall assessment of the participant's stage and degree of impairment across the continuum of early Alzheimer's Disease (AD).
Measured: Baseline to Time to Event up to Week 255
Secondary outcomes (11)
Change from Baseline in Clinical Dementia Rate Box Score (SB)
Change from baseline in Clinical Dementia Rate Box Score (SB) scores range from 0 to 18, with higher scores indicative of more impairment.
Measured: Baseline, Week 255
Change from Baseline in Montreal Cognitive Assessment (MoCA)
Change from baseline in Montreal Cognitive Assessment (MoCA). Total MoCA score is 0 to 30, with lower scores indicating greater level of impairment.
Measured: Baseline, Week 255
Change from Baseline in the Category Fluency - Language, Executive Function, Semantic Memory
Change from baseline in the Category Fluency - Language, Executive Function, Semantic Memory. The total score reflects the sum of correct responses generated across all categories presented, with higher values indicating better performance.
Measured: Baseline, Week 255
Change from Baseline in the Continuous Paired Associate Learning (CPAL)
Change from baseline in Continuous Paired Associate Learning (CPAL) - Visual episodic memory.
Measured: Baseline, Week 255
Change from Baseline in International Shopping List Test (ISLT) - Verbal Episodic Mem
Change from baseline in the International Shopping List Test (ISLT) - verbal episodic memory.
Measured: Baseline, Week 255
Change from Baseline in International Daily Symbol Substitution Test-Medicines (iDSSTm) - Complex Attention Memory
Change from baseline in the International Daily Symbol Substitution Test-Medicines (iDSSTm) - complex attention memory.
Measured: Baseline, Week 255
Change from Baseline in Cognitive Function Index (CFI)
Change from baseline in the Cognitive Function Index (CFI).
Measured: Baseline, Week 255
Change from Baseline in Mild Behavioral Impairment Checklist (MBI-C)
Change from baseline in the Mild Behavioral Impairment Checklist (MBI-C) The MBI-C total score range is 0 to 102, with higher scores indicating greater impairment.
Measured: Baseline, Week 255
Change from Baseline in Alzheimer's Disease Cooperative Study (ADCS) Activities of Daily Living - Prevention Instrument (ADCS-ADL-PI)
Change from baseline in the Activities of Daily Living - Prevention Instrument total scores range from 0 to 54, with higher scores indicating better performance.
Measured: Baseline, Week 255
Pharmacokinetics: Serum Concentrations of Remternetug
PK: serum concentration of remternetug.
Measured: Baseline through Week 255
Number of Participants with Treatment Emergent Anti-Drug Antibodies (TE-ADAs)
Number of participants with treatment emergent anti-drug antibodies (TE-ADAs).
Measured: Baseline through Week 255
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Oct 2024
- Study start24 Oct 2024
- Primary completionApr 2029 (estimated)
- Study completionOct 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alzheimer's DiseaseStudies of the same condition, open and under way.
- More trials run by Eli Lilly and CompanyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 1,400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Eli Lilly and Company
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Study director, Eli Lilly and Company
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06653153
- Sponsor's protocol ID
- 27183
- Other IDs
- J1G-MC-LAKI, 2024-515656-20-00
- Status last verified
- Oct 2026
- First submitted
- 21 Oct 2024
- Last updated
- 7 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Study at a glance
From the registry record, last updated by the sponsor on 7 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline
- ClinicalTrials.gov ID
- NCT06653153
- Acronym / sponsor ID
- 27183
- Conditions
- Alzheimer's Disease
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,400 participants (estimated)
- Lead sponsor
- Eli Lilly and CompanyIndustry (pharma, biotech, devices)
- Study start
- 24 Oct 2024 (actual)
- Primary completion
- Apr 2029 (estimated)
- Study completion
- Oct 2030 (estimated)
- First posted
- 22 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo.
Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Remternetug | Experimental | Drug: RemternetugRemternetug administered subcutaneously (SC). |
| Placebo | Placebo comparator | Drug: PlaceboPlacebo administered SC. |
Who may qualify
- Ages
- 55 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Have a phosphorylated tau (P-tau) result consistent with the presence of amyloid pathology.
- Have a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.
- Have adequate literacy, vision, and hearing for neuropsychological testing at screening.
- Have a Mini Mental Status Exam (MMSE) score consistent with no to minimal cognitive impairment.
- Have a Functional Activities Questionnaire (FAQ) score consistent with no to minimal functional impairment.
Key exclusion criteria (10 listed)
- Have dementia or significant other neurological disease that can affect cognition.
- Have current serious or unstable illnesses that in the investigator's opinion, could interfere with the analyses of the study.
- Have a history of cancer that, in the investigator's opinion, has a high risk of recurrence.
- Have a history of clinically significant multiple or severe drug allergies, or hypersensitivity reactions.
- Have a clinically important laboratory test result or other abnormality as determined by investigator, prior to randomization, that could be detrimental to the participant or could compromise the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RemternetugAlso: LY3372993Administered SC | Drug | Remternetug |
| PlaceboAdministered SC | Drug | Placebo |
Primary outcome
Time to Clinically Meaningful Progression as Measured by Clinical Dementia Rate Scale (CDR)
Time frame: Baseline to Time to Event up to Week 255
Time to clinically meaningful progression as measured by CDR. CDR is a clinician-rated scale that provides an overall assessment of the participant's stage and degree of impairment across the continuum of early Alzheimer's Disease (AD).
11 secondary outcomes
Change from Baseline in Clinical Dementia Rate Box Score (SB)
Time frame: Baseline, Week 255
Change from Baseline in Montreal Cognitive Assessment (MoCA)
Time frame: Baseline, Week 255
Change from Baseline in the Category Fluency - Language, Executive Function, Semantic Memory
Time frame: Baseline, Week 255
Change from Baseline in the Continuous Paired Associate Learning (CPAL)
Time frame: Baseline, Week 255
Change from Baseline in International Shopping List Test (ISLT) - Verbal Episodic Mem
Time frame: Baseline, Week 255
Change from Baseline in International Daily Symbol Substitution Test-Medicines (iDSSTm) - Complex Attention Memory
Time frame: Baseline, Week 255
Change from Baseline in Cognitive Function Index (CFI)
Time frame: Baseline, Week 255
Change from Baseline in Mild Behavioral Impairment Checklist (MBI-C)
Time frame: Baseline, Week 255
Change from Baseline in Alzheimer's Disease Cooperative Study (ADCS) Activities of Daily Living - Prevention Instrument (ADCS-ADL-PI)
Time frame: Baseline, Week 255
Pharmacokinetics: Serum Concentrations of Remternetug
Time frame: Baseline through Week 255
Number of Participants with Treatment Emergent Anti-Drug Antibodies (TE-ADAs)
Time frame: Baseline through Week 255
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Oct 2026.
- Individual participant dataSharing planned: Yes. Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Related trials for Alzheimer's Disease
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease
Alzheimer's Disease
RecruitingObservational study
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study
Alzheimer's Disease (AD)
RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
RecruitingPhase 3
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Alzheimer's Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) study director
Eli Lilly and Company
262 sites in 10 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Remternetug in people with Alzheimer's Disease, run by Eli Lilly and Company at 262 sites in 10 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 7 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 262 sites in United States, China, Japan, Canada, South Korea and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to Clinically Meaningful Progression as Measured by Clinical Dementia Rate Scale (CDR) (time frame: Baseline to Time to Event up to Week 255). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2026.